Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
|Videos|April 28, 2011
Dr. Cobb Discusses the Implications of the VBID
Author(s)Patrick W. Cobb, MD
Dr. Cobb Discusses the Implications of the Value Based Insurance Design
Advertisement
Patrick W. Cobb, MD, FACP the President of the Community Oncology Alliance (COA) Discusses the Implications of the Value Based Insurance Design
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC
2
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
3
The OncFive: Top Oncology Articles for the Week of 7/12
4
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
5